Velocity is the world’s largest organization of fully integrated clinical research sites. With 80 sites and more than 220 investigators, Velocity partners with pharmaceutical and biotechnology companies to research new drugs, medical devices, diagnostics, and combination products that could improve human health and wellbeing. Velocity offers unified research site solutions to efficiently provide the right patients, investigators, and research staff for clinical trials across the U.S. and Europe. The company also operates a technology hub in India, where it is unlocking a new era in clinical research by developing innovative systems to leverage expansive site, patient, and historical performance data. To learn more about how Velocity delivers high-quality data, exemplary patient care, and unprecedented efficiency for clinical trials at any scale, visit VelocityClinical.com.
Six Velocity Principal Investigators Co-Author Article Published in Nature Medicine September 28, 2023 10:41am
Six Velocity Principal Investigators coauthored an article recently published in Nature Medicine. The article covers the results of a Phase 2/3 trial of the Omicron BA.4/BA.5-containing bivalent mRNA-1273.222 vaccine with the ancestral Wuhan-Hu-1 mRNA-1273 as booster doses. Beyond yielding promising results, the trial has set the groundwork for swiftly addressing circulating variants as SARS-CoV-2 continues ... Read more
The post Six Velocity Principal Investigators Co-Author Article Published i...
View this post
‘New Era’ for Alzheimer’s Treatments Spur Researcher Optimism September 21, 2023 11:50am
After battling on the frontline for many years against an aggressive and elusive opponent, Michael Hemphill, MD and the Velocity team in Savannah, GA, believe we’ve entered an exciting “new era” in the fight against Alzheimer’s disease and dementia. Velocity conducts clinical trials related to disorders of the nervous system in Savannah as an embedded research ... Read more
The post ‘New Era’ for Alzheimer’s Treatments Spur Researcher Optimism appeared first on Velocity Clinical R...
View this post
Velocity Syracuse Team Advances Important Alzheimer’s Trials September 21, 2023 11:50am
Alzheimer’s is currently ranked as the seventh leading cause of death in the United States and is the most common cause of dementia among older adults. Alzheimer’s disease, a cruel and pernicious affliction, is a brain disorder that slowly destroys memory, thinking skills, and eventually, the ability to carry out even the most simple and ... Read more
The post Velocity Syracuse Team Advances Important Alzheimer’s Trials appeared first on Velocity Clinical Research.
View this post
Velocity Launches Vaccine Council to Accelerate Research Excellence (CARE) September 14, 2023 11:18am
Velocity has introduced the Vaccine Council to Accelerate Research Excellence (CARE). This council will bring world-class operational, patient recruitment, and trial conduct oversight to all Velocity sites conducting vaccine studies in the U.S. and Europe. Led by some of the world’s top vaccine Principal Investigators, including Brandon Essink, MD, CPI, the Vaccine CARE Council will ... Read more
The post Velocity Launches Vaccine Council to Accelerate Research Excellence (CARE) appeared first...
View this post
Julio Rosenstock, MD Co-Authored an Article Published in NEJM September 13, 2023 10:55am
Another positive step in obesity research: Julio Rosenstock, MD, is a co-author of an article now featured on The New England Journal of Medicine homepage, and in the publication’s weekend email briefing. From the article, Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity: “At week 26, the mean change from baseline in body ... Read more
The post Julio Rosenstock, MD Co-Authored an Article Published in NEJM appeared first on Velocity Clinical Research.
View this post
Velocity Acquires Site in Berlin, Fourth in Germany August 21, 2023 1:01am
What do you get when you have a business economist with nursing experience? In this case, it’s one of the founding members of a clinical trials site in Berlin, Germany, which has become the latest member of Velocity’s integrated site network in Europe. Dominic Clavell, European General Manager, explained, “This is Velocity’s fourth site acquisition ... Read more
The post Velocity Acquires Site in Berlin, Fourth in Germany appeared first on Velocity Clinical Research.
View this post
